In patients with pretreated metastatic colorectal cancer (mCRC), trifluridine/tipiracil (FTD–TPI) + bevacizumab has superior efficacy compared with FTD–TPI alone. However, real-world data on outcomes and comparisons with other established therapies including regorafenib are scarce.
Additionally, evidence suggests that molecular alterations, such as KRASG12 mutations, may affect FTD–TPI efficacy. We aimed to compare clinical outcomes of patients with mCRC treated with FTD–TPI + bevacizumab, FTD–TPI, or regorafenib across molecular subgroups.
ESMO Open published a clinical update in Oncology on 26 Mar 2026.
The item focuses on Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study.
Review the original article for the full source wording and details.